Obésité et risque de COVID-19 sévère.

[en] Obesity represents a higher risk of severe COVID-19 infection, which may lead to the requirement of a mechanical ventilation in intensive care units and premature death. The underlying mechanisms are multiple: alteration of the respiratory performance, presence of comorbidities such as diabetes, hypertension or obstructive sleep apnea, finally inadequate and excessive immunological responses, possibly aggravated by ectopic intrathoracic fat depots. Thus, COVID-19 may challenge the so-called « obesity paradox » commonly reported by intensivists in patients with acute respiratory distress syndrome. These findings require reinforced preventive and curative measures among obese patients to limit the risk of progression towards an unfavorable outcome in case of COVID-19.

Disciplines :

Immunology & infectious disease
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Obésité et risque de COVID-19 sévère.

Alternative titles :

[en] Obesity and risk of severe COVID-19

Publication date :

2020

Journal title :

Revue Médicale Suisse

ISSN :

1660-9379

Publisher :

Medecine et Hygiène, Switzerland

Volume :

Issue :

695

Pages :

1115-1119

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 08 June 2020

Statistics

Number of views

247 (4 by ULiège)

Number of downloads

3 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

See more details

Bibliography

Tadini E, Papamidimitriou-Olivgeris M, Opota O, et al. SARS-CoV-2, un point dans la tourmente. Rev Med Suisse 2020;16: 917-23.
Kosinski C, Zanchi A, Wojtusciszyn A. Diabète et infection à COVID-19. Rev Med Suisse 2020;16:939-43.
Abbas AM, Fathy SK, Fawzy AT, et al. The mutual effects of COVID-19 and obesity. Obes Med 2020; May 6:100250. doi: 10.1016/j.obmed.2020.100250. [Epub ahead of print].
Muscogiuri G, Pugliese G, Barrea L, et al. Obesity: The «Achilles heel» for COVID-19? Metabolism 2020; Apr 27;108:154251. doi: 10.1016/j.metabol.2020.154251. [Epub ahead of print].
Samuels JD. Obesity and severe COVID-19 disease: a strong association. Obesity (Silver Spring). 2020 May 4. doi: 10.1002/oby.22866. [Epub ahead of print].
Kalligeros M, Shehadeh F, Mylona EK, et al. Association of obesity with disease severity among patients with COVID-19. Obesity (Silver Spring). 2020 Apr 30. doi: 10.1002/oby.22859. [Epub ahead of print].
Fruhbeck G, Baker JL, Busetto L, et al. European Association for the Study of Obesity Position Statement on the global COVID-19 pandemic. Obes Facts 2020;13:292-6.
Fumeaux T. Covid-19: que sait-on des patients admis en soins intensifs? Rev Med Suisse 2020;16:756.
Milner JJ, Beck MA. The impact of obesity on the immune response to infection. Proc Nutr Soc 2012;71:298-306.
Green WD, Beck MA. Obesity altered T cell metabolism and the response to infection. Curr Opin Immunol 2017;46:17.
Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc 2017;14:S406-S9.
Luzi L, Radaelli MG. Influenza and obesity: its odd relationship and the lessons for COVID-19 pandemic. Acta Diabetol. 2020 Apr 5. doi: 10.1007/ s00592-020-01522-8. [Epub ahead of print].
Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 Apr 22. doi: 10.1001/jama.2020.6775. [Epub ahead of print].
Buscemi S, Buscemi C, Batsis JA. There is a relationship between obesity and COVID-19 but more information is needed. Obesity (Silver Spring). 2020 May 12. doi: 10.1002/oby.22883. [Epub ahead of print].
Petrakis D, Margina D, Tsarouhas K, et al. Obesity a risk factor for increased COVID19 prevalence, severity and lethality (Review). Mol Med Rep. 2020 May 5. doi: 10.3892/mmr.2020.11127. [Epub ahead of print].
Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020 Apr 9. doi: 10.1002/ oby.22831. [Epub ahead of print].
Watanabe M, Risi R, Tuccinardi D, et al. Obesity and SARS-CoV-2: a population to safeguard. Diabetes Metab Res Rev 2020; Apr 21:e3325. doi: 10.1002/dmrr.3325. [Epub ahead of print].
Caussy C, Wallet F, Laville M, et al. Obesity is associated with severe forms of COVID-19. Obesity (Silver Spring). 2020 Apr 21. doi: 10.1002/oby.22842. [Epub ahead of print].
Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020 Apr 9. doi: 10.1093/cid/ciaa415. [Epub ahead of print].
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalisation and critical illness among 4, 103 patients with Covid-19 disease in New York city. doi: 10.1101/2020.04.08.20057794.
Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characterstics and prognosis of in-patients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020; doi: 10.1007/ s00125-020-05180-x.
Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 mortality. Obesity (Silver Spring). 2020 Apr 1. doi: 10.1002/oby.22818. [Epub ahead of print].
Scheen AJ, Marre M, Thivolet C. Prognostic factors in patients with diabetes hospitalized for COVID-19: Diabetes Metab 2020; In press.
Sattar N, McInnes IB, McMurray JJV. Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020 Apr 22. doi: 10.1161/ CIRCULATIONAHA.120.047659. [Epub ahead of print].
Costa H, Jacob M, Pereira R, et al. COVID-19 ventilatory phenotypes and obesity: is there a relationship? Obesity (Silver Spring). 2020 May 8. doi: 10.1002/ oby.22877. [Epub ahead of print].
Severin R, Arena R, Lavie CJ, et al. Respiratory muscle performance screening for infectious disease management following COVID-19: a highly pressurized situation. Am J Med. 2020 Apr 25. doi: 10.1016/j.amjmed.2020.04.003. [Epub ahead of print].
Huang JF, Wang XB, Zheng KI, et al. Obesity hypoventilation syndrome and severe COVID-19. Metabolism 2020; Apr 22;108:154249. doi: 10.1016/j.metabol.2020.154249. [Epub ahead of print].
Kreutz R, Algharably EAE, Azizi M, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020 Apr 15. doi: 10.1093/cvr/cvaa097. [Epub ahead of print].
Zuin M, Rigatelli G, Zuliani G, et al. Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis. J Infect. 2020 Apr 11. doi: 10.1016/j. jinf.2020.03.059. [Epub ahead of print].
McSharry D, Malhotra A. Potential influences of obstructive sleep apnea and obesity on COVID-19 severity. J Clin Sleep Med. 2020 May 1. doi: 10.5664/jcsm.8538. [Epub ahead of print].
Perico L, Benigni A, Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. Nephron 2020; Mar 23:1-9. doi: 10.1159/000507305. [Epub ahead of print].
Kissling S, Pruijm M. Vue sur le COVID-19 depuis la néphrologie. Rev Med Suisse 2020;16:842-4.
Zheng KI, Gao F, Wang XB, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism 2020; Apr 19;108:154244. doi: 10.1016/j.metabol.2020.154244. [Epub ahead of print].
Prins GH, Olinga P. Potential implications of COVID-19 in non-alcoholic fatty liver disease. Liver Int. 2020 Apr 19. doi: 10.1111/liv.14484. [Epub ahead of print].
Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020 Apr 22. doi: 10.1111/jth.14869. [Epub ahead of print].
Casini A, Fontana P, Glauser F, et al. Risque thrombotique veineux induit par le SARS-CoV-2: prévalence, recommandations et perspectives. Rev Med Suisse 2020;16:951-4.
Esser N, L'Homme L, De Roover A, et al. Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia 2013;56:2487-97.
Malavazos AE, Corsi Romanelli MM, Bandera F, et al. Targeting the adipose tissue in COVID-19. Obesity (Silver Spring). 2020 Apr 21. doi: 10.1002/ oby.22844. [Epub ahead of print].
Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity (Silver Spring). 2020 Apr 27. doi: 10.1002/ oby.22856. [Epub ahead of print].
Michalakis KIlias I. SARS-CoV-2 infection and obesity: Common inflammatory and metabolic aspects. Diabetes Metab Syndr 2020; 14:469-71.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 2020;318:E736-E41.
Ryan PM, Caplice NM. Is adipose tissue a reservoir for viral spread, immune activation and cytokine amplification in COVID-19. Obesity (Silver Spring). 2020 Apr 21. doi: 10.1002/oby.22843. [Epub ahead of print].
Zhao L. Obesity accompanying COVID-19: the role of epicardial fat. Obesity (Silver Spring). 2020 May 4. doi: 10.1002/oby.22867. [Epub ahead of print].
Ni YN, Luo J, Yu H, et al. Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis. Crit Care 2017;21:36.
Acharya P, Upadhyay L, Qavi A, et al. The paradox prevails: Outcomes are better in critically ill obese patients regardless of the comorbidity burden. J Crit Care 2019;53:25-31.
Jose RJ, Manuel A. Does COVID-19 disprove the obesity paradox in ARDS? Obesity (Silver Spring). 2020 Apr 15. doi: 10.1002/oby.22835. [Epub ahead of print].
Flint SW, Tahrani AA. COVID-19 and obesity-lack of clarity, guidance, and implications for care. Lancet Diabetes Endocrinol. 2020 Apr 29. doi: 10.1016/ S2213-8587(20)30156-X. [Epub ahead of print].
Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020 May 4. doi: 10.1016/S01406736(20)31024-2. [Epub ahead of print].
Ong SWX, Young BE, Leo YS, et al. Association of higher body mass index (BMI) with severe coronavirus disease 2019 (COVID-19) in younger patients. Clin Infect Dis. 2020 May 8. doi: 10.1093/ cid/ciaa548. [Epub ahead of print].
Stefan N, Birkenfeld AL, Schulze MB, et al. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020 Apr 23. doi: 10.1038/ s41574-020-0364-6. [Epub ahead of print].
Hall G, Laddu DR, Phillips SA, et al. A tale of two pandemics: How will COVID-19 and global trends in physical inactivity and sedentary behavior affect one another? Prog Cardiovasc Dis. 2020 Apr 8. doi: 10.1016/j.pcad.2020.04.005. [Epub ahead of print].
Nieman DC. COVID-19: A tocsin to our aging, unfit, corpulent, and immunodeficient society. J Sport Health Sci. 2020 May 7. doi: 10.1016/j.jshs.2020.05.001. [Epub ahead of print]
Butler MJ, Barrientos RM. The impact of nutrition on COVID-19 susceptibility and long-term consequences. Brain Behav Immun. 2020 Apr 18. doi: 10.1016/j. bbi.2020.04.040. [Epub ahead of print].
Laddu DR, Lavie CJ, Phillips SA, et al. Physical activity for immunity protection: Inoculating populations with healthy living medicine in preparation for the next pandemic. Prog Cardiovasc Dis. 2020 Apr 9. doi: 10.1016/j.pcad.2020.04.006. [Epub ahead of print].
Alzghari SK, Acuna VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol 2020;127: Apr 21;127:104380. doi: 10.1016/j. jcv.2020.104380. [Epub ahead of print].
Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev 2020; May 4:102567. doi: 10.1016/j. autrev.2020.102567. [Epub ahead of print].
Yeo C, Ahmed S, Oo AM, et al. COVID-19 and obesity-the management of pre- and post-bariatric patients amidst the COVID-19 pandemic. Obes Surg. 2020 May 9. doi: 10.1007/s11695-020-04670-6. [Epub ahead of print].
Rubino F, Cohen RV, Mingrone G, et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. Lancet Diabetes Endocrinol. 2020 May 7. doi: 10.1016/S22138587(20)30157-1. [Epub ahead of print].

Name	Provider / Domaine	Expiration	Description
JSESSIONID	Oracle Corporation www.uliege.be	Session	General purpose platform session cookie, used by sites written in JSP. Usually used to maintain an anonymous user session by the server.
CookieScriptConsent	CookieScript .uliege.be	1 year	This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.

Name	Provider / Domaine	Expiration	Description
_pk_id	InnoCraft Ltd .uliege.be	1 year	Used to store a few details about the user such as the unique visitor ID
_pk_ses	InnoCraft Ltd .uliege.be	30 minutes	Short lived cookies used to temporarily store data for the visit
_pk_ref	InnoCraft Ltd .uliege.be	6 months	Used to store the attribution information, the referrer initially used to visit the website